Scholarlink

<p>Glioblastoma stem cells (GSCs), which exhibit resistance to multiple treatments, are a prominent driver of postoperative glioblastoma (GBM) relapse. Reducing the GSC population holds promise in GBM therapy but remains challenging due to the difficulty in coordinating the complex cytokine signalling programs and extracellular matrix characteristics that induce GSC expansion. Here we develop a biohybrid chiral hydrogel that allows intracavity implantation after GBM surgical debulking to comprehensively regulate GSC stemness, enhancing postoperative therapy. The hydrogel encapsulates GSC-membrane-coated nanoparticles that serve as potent decoys to broadly neutralize GSC-targeted pro-stemness and chemotaxis cytokines, allowing functional blocking and hydrogel infiltration of GSCs. Moreover, we showed that the <span>D</span>-chiral biohybrid hydrogel, in contrast to its <span>L</span>- and <span>DL</span>-chiral counterparts, further diminished the GSC stemness phenotype via <span>D</span>-chiral-geometry-regulated mechanotransduction pathways. In three orthotopic intracranial GBM models, the multi-pronged inhibition of GSC stemness enhanced gold-nanocluster-based hydrogel-scaffold-sensitized radioimmunotherapy, enabling the suppression of GBM relapse post-resection. This integrated regulation of biochemical and biophysical cues shows the potential for treating cancer-stem-cell-enriched malignancies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A biohybrid chiral hydrogel enhances preclinical postoperative glioblastoma therapy by multi-pronged inhibition of tumour stemness

  • 期刊论文

  • 发表日期：

    2025年12月26日

查看全文
  • Tingting Cui,
  • Sixue Chen,
  • Siqin Liu,
  • Xuegang Niu,
  • Jun Wang,
  • Rujiang Ao,
  • Huilan Cai,
  • Hongwei Huang,
  • Meili Yu,
  • Shanshan Peng,
  • Xiaoyuan Chen,
  • Lisen Lin

摘要

Glioblastoma stem cells (GSCs), which exhibit resistance to multiple treatments, are a prominent driver of postoperative glioblastoma (GBM) relapse. Reducing the GSC population holds promise in GBM therapy but remains challenging due to the difficulty in coordinating the complex cytokine signalling programs and extracellular matrix characteristics that induce GSC expansion. Here we develop a biohybrid chiral hydrogel that allows intracavity implantation after GBM surgical debulking to comprehensively regulate GSC stemness, enhancing postoperative therapy. The hydrogel encapsulates GSC-membrane-coated nanoparticles that serve as potent decoys to broadly neutralize GSC-targeted pro-stemness and chemotaxis cytokines, allowing functional blocking and hydrogel infiltration of GSCs. Moreover, we showed that the D-chiral biohybrid hydrogel, in contrast to its L- and DL-chiral counterparts, further diminished the GSC stemness phenotype via D-chiral-geometry-regulated mechanotransduction pathways. In three orthotopic intracranial GBM models, the multi-pronged inhibition of GSC stemness enhanced gold-nanocluster-based hydrogel-scaffold-sensitized radioimmunotherapy, enabling the suppression of GBM relapse post-resection. This integrated regulation of biochemical and biophysical cues shows the potential for treating cancer-stem-cell-enriched malignancies.